Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Syndax Pharmaceuticals Ownership Summary


Syndax Pharmaceuticals is owned by 117.83% institutional investors, 1.29% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 12.11% of SNDX shares. Vanguard Health Care Inv is the top mutual fund, with 3.50% of its assets in Syndax Pharmaceuticals shares.

SNDX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSyndax Pharmaceuticals117.83%1.29%-19.12%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de10.46M12.11%$97.93M
Kynam capital management, lp8.52M9.87%$79.79M
Blackrock7.91M9.28%$162.33M
Goldman sachs group5.95M6.97%$78.67M
Vanguard group4.88M5.71%$64.54M
Wellington management group llp4.23M4.96%$55.98M
Eversept partners, lp4.07M4.71%$38.07M
State street3.62M4.25%$74.37M
Stempoint capital lp2.37M2.75%$22.22M
Point72 asset management2.13M2.46%$19.92M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp8.52M8.59%$79.79M
Stempoint capital lp2.37M7.13%$22.22M
Lion point capital, lp55.00K3.81%$727.10K
Eversept partners, lp4.07M3.50%$38.07M
Sphera funds management1.57M3.45%$14.72M
Aisling capital management lp1.32M3.43%$12.33M
Exome asset management318.90K3.17%$4.22M
Kingdon capital management2.10M2.65%$19.67M
Prosight management, lp1.08M2.47%$10.11M
Ghost tree capital350.00K2.25%$7.19M

Top Buyers

HolderShares% AssetsChange
Goldman sachs group5.95M0.01%4.34M
Blackrock funding, inc. /de10.46M0.00%1.91M
Ubs group1.03M0.00%882.38K
Qube research1.67M0.02%831.07K
Adage capital partners gp1.43M0.02%800.80K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---2.27M
Orbimed advisors---1.93M
Point72 asset management2.13M0.04%-1.88M
Bvf inc/il---1.88M
Balyasny asset management126.14K0.00%-1.69M

New Positions

HolderShares% AssetsChangeValue
Cubist systematic strategies358.07K0.03%358.07K$4.73M
Exome asset management318.90K3.17%318.90K$4.22M
Boothbay fund management128.84K0.02%128.84K$1.21M
Man group121.54K0.00%121.54K$1.61M
Stonepine capital management92.90K0.85%92.90K$870.01K

Sold Out

HolderChange
Tfc financial management-1.00
Nelson, van denburg & campbell wealth management group-13.00
Riggs asset managment-26.00
Svb wealth-27.00
Stephens consulting-30.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025232-101,730,1911.68%1170.86%116-3.33%651.56%
Mar 31, 20252332.19%100,944,7752.97%1170.90%119-7.03%6510.17%
Dec 31, 2024216-5.68%91,955,1243.35%1070.99%119-4.03%58-1.69%
Sep 30, 202422511.39%88,858,8691.79%1040.99%12110.00%59-3.28%
Jun 30, 20242002.56%87,296,966-3.26%1020.66%109-3.54%6011.11%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv2.99M3.50%-
Vanguard US Total Market Shares ETF2.60M3.01%4.69K
Vanguard Total Stock Mkt Idx Inv2.56M2.98%-56.87K
iShares Russell 2000 ETF1.99M2.31%-37.80K
SPDR® S&P Biotech ETF1.53M1.78%37.73K
Eventide Healthcare & Life Sciences I1.18M1.37%-
Franklin Biotechnology Discv A(acc)USD1.02M1.18%-
Vanguard Institutional Extnd Mkt Idx Tr935.83K1.09%-408.69K
BNP Paribas Health Cr Innovtr Cl Cap832.29K0.97%-826.00
Fidelity Small Cap Index831.63K0.97%-2.46K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 08, 2025Metzger Michael A Chief Executive OfficerSell$2.58M
Aug 14, 2025Podlesak Dennis-Sell$272.52K
Aug 15, 2025Podlesak Dennis-Sell$298.41K
Aug 18, 2025Podlesak Dennis-Sell$304.17K
Jul 16, 2025Goldan Keith A. Chief Financial OfficerSell$12.03K

Insider Transactions Trends


DateBuySell
2025 Q3-6
2025 Q24-
2025 Q1-4
2024 Q21-
2024 Q1--

SNDX Ownership FAQ


Who Owns Syndax Pharmaceuticals?

Syndax Pharmaceuticals shareholders are primarily institutional investors at 117.83%, followed by 1.29% insiders and -19.12% retail investors. The average institutional ownership in Syndax Pharmaceuticals's industry, Biotech Stocks , is 306.59%, which Syndax Pharmaceuticals falls below.

Who owns the most shares of Syndax Pharmaceuticals?

Syndax Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (10.46M shares, 12.11%), Kynam capital management, lp (8.52M shares, 9.87%), and Blackrock (7.91M shares, 9.28%). Together, they hold 31.26% of Syndax Pharmaceuticals’s total shares outstanding.

Does Blackrock own Syndax Pharmaceuticals?

Yes, BlackRock owns 9.28% of Syndax Pharmaceuticals, totaling 7.91M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 162.33M$. In the last quarter, BlackRock increased its holdings by 354.33K shares, a 4.69% change.

Who is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 8.59% of its assets in 8.52M Syndax Pharmaceuticals shares, valued at 79.79M$.

Who is the top mutual fund holder of Syndax Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Syndax Pharmaceuticals shares, with 3.50% of its total shares outstanding invested in 2.99M Syndax Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools